



Rib-X Pharmaceuticals
300 George Street, Suite 301
New Haven, CT 06511

March 27, 2012

Thomas Slama, MD, FIDSA
President
Infectious Diseases Society of America
1300 Wilson Boulevard, Suite 300
Arlington, VA 22209

Dear Dr. Slama,

Rib-X Pharmaceuticals is a biotechnology company located in New Haven, CT. We are developing broad spectrum antibiotics with superior coverage, safety, and convenience to deliver new standards of care for patients with serious infections. We are writing this letter in support of the I.D.S.A. in its efforts to increase the availability of antibiotics that are effective against multi-drug resistant microorganisms. The I.D.S.A. almost single handedly has been sounding the alarm now for more than 10 years over the frightening increase and spread of multi-drug resistant Gram-positive and Gram-negative organisms. At the same time, the number of large pharmaceutical companies engaged in the discovery and development of antibiotics has plummeted, and funding for innovative start-ups focusing on this medical need has been limited. The origins of this predicament are multi-factorial, however, there can be no doubt that the incentives for pharmaceutical companies to engage in R&D in this area are generally perceived to have substantially declined over the same time period. While not the total solution to the problem, we believe that the Special Population Limited Medical Use (SPLMU) drug approval pathway for new antibiotics is a potentially very useful mechanism for improving access to life-saving antibiotics targeting the most difficult to treat organisms. At the same time, other approaches, such as the GAIN bill and continuing dialog with FDA, need to be actively pursued. Rib-X Pharmaceuticals was founded on the belief that innovative science can provide answers to these pressing needs. We applaud the efforts of I.D.S.A. to help improve the environment in which antibiotic R&D is conducted.

Sincerely,

A handwritten signature in black ink, appearing to read "Mark Leuchtenberger".

Mark Leuchtenberger
President and Chief Executive Officer

cc: S. Hopkins, A.D. Sabatelli